eNewsroom for: Novoteris

Novoteris is a privately held limited liabilities corporation that is managed by a group of international industry veterans and clinicians involved in developing and producing innovative, cutting-edge medical products.

News from Novoteris:

Novoteris, LLC Announces $2.8 Million Award from Cystic Fibrosis Foundation Therapeutics to Support Development of Inhaled Nitric Oxide Antimicrobial Therapy

GARDEN GROVE, Calif., June 23, 2015 /PRNewswire/ —¬†Novoteris, LLC announced today a $2.8 million agreement with Cystic Fibrosis Foundation Therapeutics Inc. (CFFT), the nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation, to develop an inhaled nitric oxi…

Novoteris, LLC., Medical Device and Pharmaceutical Product Innovators, Receives Orphan Drug Designation for Nitric Oxide for the Treatment of Cystic Fibrosis

Application Brings Years of Work with Nitric Oxide Gas for Antimicrobial Use to Clinical Fruition GARDEN GROVE, Calif., Oct. 9, 2013 /PRNewswire/ —¬†Novoteris, LLC., a clinical stage medical device and pharmaceutical developer focused on innovative applications for nitric oxide gas where i…